Arbor Biotechnologies

Arbor Biotechnologies: Series C Funding Round

Arbor Biotechnologies has successfully raised $215M in Series C funding, reaching a valuation of $800M.

Company Overview

Gene editing technologies

Funding Details

The Series C round was led by Lightspeed Venture Partners, with participation from Redmile Group, Agent Capital, Amplitude Ventures.

Company Information

• Headquarters: 830 Winter Street, Waltham, MA 02451
• Founded: 2016
• Employees: 100+
• Category: Biotech

Investment

Arbor Biotechnologies plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Lightspeed Venture Partners: Verified investor in Series C
• Redmile Group: Verified investor in Series C
• Agent Capital: Verified investor in Series C
• Amplitude Ventures: Verified investor in Series C